Volume 94 Issue 11 | p. 14 | News of The Week
Issue Date: March 14, 2016 | Web Date: March 11, 2016

UCLA gets windfall from Xtandi rights

University, researchers, and others to share more than $1 billion
Department: Business
Keywords: pharmaceuticals, licensing, drugs, cancer

The University of California, Los Angeles, has joined an elite group of academic institutions to hit the drug discovery jackpot. Royalty Pharma, a company that buys drug royalty rights, has paid $1.14 billion for part of the royalty rights for Medivation’s prostate cancer drug Xtandi, which was discovered by UCLA chemist Michael Jung and physician Charles Sawyers.

The university will receive about half of that sum. Also benefiting are UCLA’s chemistry department, the inventors, and . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society